Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2012-03-29. The firm does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The firm is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Industry: Pharmaceutical Preparations Peers: PharmaCyte Biotech Inc Exagen Inc TYME TECHNOLOGIES, INC. Immunome Inc Lantern Pharma Inc Lite Strategy Inc Minerva Neurosciences Inc Sera Prognostics Inc TScan Therapeutics Inc